SecBot SecBot
424B5 ·Filed May 8, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-214985
Notable filing: 424B5
Actionable Insight • Neutral

The offering is a routine capital raise for a pre-revenue biotech with positive Phase 3 data. Monitor the timing of the NDA submission and any updates on the XR tablet Phase 3 trial (CHAPTER-3). The modest dilution is offset by extended cash runway, but no near-term catalyst from this filing alone.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$29.95
T+0 close · May 8, 2026 · via day close
Latest settled
+11.59%
T+60 · $33.42
Vs SPY
+7.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $29.95entry
  2. T+1 · 6mo ago 0.00%α +0.14% · $29.95
  3. T+5 · 6mo ago −3.81%α −3.72% · $28.81
  4. T+20 · 5mo ago +5.51%α +5.81% · $31.60
  5. T+60 · 3mo ago +11.59%α +7.19% · $33.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary shares at $29.68 per share, with an option for an additional 581,199 shares. The offering is expected to raise approximately $107.5 million in net proceeds (or $123.7 million if the option is fully exercised), which will be used to fund late-stage clinical programs, US commercialization efforts, and working capital. The company reported $247 million in cash as of March 31, 2026, and the offering extends its runway into the first half of 2028.

Key Facts

  • Offering 3,874,664 shares at $29.68 per share, total gross proceeds of $115 million
  • Underwriters have a 30-day option to purchase up to an additional 581,199 shares
  • Net proceeds estimated at $107.5 million ($123.7 million with option exercise)
  • Proceeds to fund R&D for late-stage programs, US commercialization, and working capital
  • Cash and cash equivalents of approximately $247 million as of March 31, 2026
  • Immediate dilution of $23.51 per share for new investors based on December 31, 2025 book value
  • Shares outstanding will increase from 65,210,590 to up to 69,666,453 (if option exercised)
  • Company plans to submit NDA for deucrictibant IR capsules in H1 2026

Financial Impact

Dilution of ~5.9% to existing shareholders; net proceeds of $107.5M extend runway into H1 2028

dilutioncash runway

Risk Factors

  • Immediate dilution of $23.51 per share for new investors
  • No revenue, pre-commercial stage; reliance on regulatory approval
  • Potential further dilution if additional capital is needed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-214985
Document: d36127dexfilingfees.htm0001193125-26-214985
Document: 0001193125-26-214985-index-headers.html0001193125-26-214985
Document: 0001193125-26-214985-index.html0001193125-26-214985
Document: 0001193125-26-214985.txt0001193125-26-214985

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026